Literature DB >> 14671168

Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal.

Jon E Wergedal1, Katarina Veskovic, Minea Hellan, Christine Nyght, Wendy Balemans, Cesar Libanati, Filip M Vanhoenacker, Johan Tan, David J Baylink, Wim Van Hul.   

Abstract

Van Buchem disease is an autosomal recessive disease characterized by overgrowth of the skeleton. In a group of Dutch patients the disease is thought to be due to a 52-kb deletion that results in decreased expression of the SOST gene. To further characterize the disease, the morphology of the metacarpals of six adult subjects and two juveniles with Van Buchem disease were measured on hand x-rays along with nine normal adults and nine adult carriers of the disease. Serum bone formation markers, alkaline phosphatase, type I procollagen peptide, and osteocalcin, and the urinary bone resorption marker, cross-linked N-telopeptide, were determined. Van Buchem patients had increased metacarpal outer diameter, inner diameter, cortical thickness, and bone mineral density. Calculated bone volume and derived polar moment of inertia were markedly elevated (elevations of 158 +/- 33% and 497 +/- 95%, respectively) consistent with increased bone strength. Serum procollagen peptide and osteocalcin were significantly higher in Van Buchem patients. Urinary cross-linked N-telopeptide was significantly elevated in Van Buchem patients. None of these changes was found in Van Buchem carriers. These observations indicate that decreased expression of the SOST gene can lead to increased bone formation and to stronger bones.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14671168     DOI: 10.1210/jc.2003-030201

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  Circulating sclerostin in disorders of parathyroid gland function.

Authors:  Aline G Costa; Serge Cremers; Mishaela R Rubin; Donald J McMahon; James Sliney; Marise Lazaretti-Castro; Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2011-09-21       Impact factor: 5.958

Review 2.  Update on Wnt signaling in bone cell biology and bone disease.

Authors:  David G Monroe; Meghan E McGee-Lawrence; Merry Jo Oursler; Jennifer J Westendorf
Journal:  Gene       Date:  2011-11-03       Impact factor: 3.688

3.  Worth syndrome as a diagnosis for mandibular osteosclerosis.

Authors:  K Payne; A Dickenson
Journal:  Dentomaxillofac Radiol       Date:  2011-12       Impact factor: 2.419

Review 4.  Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases.

Authors:  E Michael Lewiecki
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-04       Impact factor: 5.346

5.  Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts.

Authors:  Damian C Genetos; Chrisoula A Toupadakis; Leah F Raheja; Alice Wong; Savvas E Papanicolaou; David P Fyhrie; Gabriela G Loots; Clare E Yellowley
Journal:  J Cell Biochem       Date:  2010-05-15       Impact factor: 4.429

Review 6.  Sclerostin and skeletal health.

Authors:  Maryam Sharifi; Lisa Ereifej; E Michael Lewiecki
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

7.  Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.

Authors:  Gabriela G Loots; Michaela Kneissel; Hansjoerg Keller; Myma Baptist; Jessie Chang; Nicole M Collette; Dmitriy Ovcharenko; Ingrid Plajzer-Frick; Edward M Rubin
Journal:  Genome Res       Date:  2005-06-17       Impact factor: 9.043

Review 8.  Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis.

Authors:  T J Martin; N A Sims; K W Ng
Journal:  Osteoporos Int       Date:  2008-03-13       Impact factor: 4.507

9.  Control of the SOST bone enhancer by PTH using MEF2 transcription factors.

Authors:  Olivier Leupin; Ina Kramer; Nicole M Collette; Gabriela G Loots; François Natt; Michaela Kneissel; Hansjoerg Keller
Journal:  J Bone Miner Res       Date:  2007-12       Impact factor: 6.741

10.  Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization.

Authors:  Kuniaki Ota; Patrick Quint; Ming Ruan; Larry Pederson; Jennifer J Westendorf; Sundeep Khosla; Merry Jo Oursler
Journal:  J Cell Biochem       Date:  2013-08       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.